case_images: PMC10228745_01
case_images: The representative CT images pre- and post-treatment and the change of PIVKA-II during the treatment schedule of the three patients with better outcome (A-C: case 1-3). The arrow indicated that the lesions change with the treatment.
case_images: fonc-13-1096955-g003.jpg
case_images: PMC10228745_03_fonc-13-1096955-g003.jpg
case_images: f3
case_images: TACE (one time), and camrelizumab (200 mg), the tumor disappeared, and the PIVKA-II decreased from 224 to 38 mAU/ml. The patient achieved complete response according to mRECIST (Figure 3C).
case_images: PMC10228745_02
case_images: The representative CT images pre- and post-treatment and the change of PIVKA-II during the treatment schedule of the three patients with better outcome (A-C: case 1-3). The arrow indicated that the lesions change with the treatment.
case_images: fonc-13-1096955-g003.jpg
case_images: PMC10228745_03_fonc-13-1096955-g003.jpg
case_images: f3
case_images: TACE (one time), and camrelizumab (200 mg), the tumor disappeared, and the PIVKA-II decreased from 224 to 38 mAU/ml. The patient achieved complete response according to mRECIST (Figure 3C).
case_images: PMC10228745_03
case_images: The representative CT images pre- and post-treatment and the change of PIVKA-II during the treatment schedule of the three patients with better outcome (A-C: case 1-3). The arrow indicated that the lesions change with the treatment.
case_images: fonc-13-1096955-g003.jpg
case_images: PMC10228745_03_fonc-13-1096955-g003.jpg
case_images: f3
case_images: TACE (one time), and camrelizumab (200 mg), the tumor disappeared, and the PIVKA-II decreased from 224 to 38 mAU/ml. The patient achieved complete response according to mRECIST (Figure 3C).